The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: A PET, histological and biochemical study

Enhancement of Striatal Dopaminergic Function Following Autologous Neural Cell Ecosystems (ANCE) Transplantation in a Non-Human Primate Model of Parkinson’s Disease

“…To summarize and interpret the PET data, the pre-lesion scans showed comparable striatal 18F-DOPA uptake values in the four monkeys, with Ki values ranging from 0.0073 (Mk-LY) to 0.0085 (Mk-MI), in line with previous reports (range 0.007 to 0.011 [9,11,[39][40][41]). As expected, the post-MPTP lesion scans revealed clearly diminished striatal 18F-DOPA uptakes in all four animals, as well as large interindividual variability (Table 2 and Figure 4A: three monkeys showed a decrease of about 80% whereas the fourth monkey exhibited a decrease of 17% only).…”

“…Furthermore, in the nonhuman primate (NHP) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model of PD, 18F-DOPA PET scan measure of presynaptic dopaminergic integrity is broadly used and gives valuable clues about the nigrostriatal state after MPTP intoxication [8,9]. Both in PD patients and NHP MPTP model, a low number of dopaminergic neurons in the SN is associated with a decrease in 18F-DOPA PET uptake in striatum [10,11].…”

PET imaging of dopamine transporters with [ 18 F]FE-PE2I: Effects of anti-Parkinsonian drugs

“…Although L-DOPA/benserazide is prescribed for oral intake in clinical practice, for the consistency of bioavailability among the rats, intraperitoneal between normal striatum of normal rats and unlesioned striatum of PD rat might not be possible. (42)(43)(44). In our study, although there is no statistical significance, there was a tendency of lower values of BPND in the unlesioned striatum of PD rats compared to that of normal rats.…”

Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([18F]AV-133)

“…Different from the previous study, we used a model of acute infusion of MPTP (0.2 mg/kg/day for 15 days), which is the standard model for anti-parkinsonian drug studies. In the Obeso study, the comparisons were made among four groups, controls, asymptomatic, recovered, and stable parkinsonism [34] .…”